Tourmaline Bio/$TRML
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tourmaline Bio
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
Ticker
$TRML
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
74
Website
Tourmaline Bio Metrics
BasicAdvanced
$583M
-
-$3.22
-
-
Price and volume
Market cap
$583M
52-week high
$28.08
52-week low
$11.56
Average daily volume
205K
Financial strength
Current ratio
33.868
Quick ratio
32.709
Total debt to equity
0.07
Profitability
EBITDA (TTM)
-98.405
Management effectiveness
Return on assets (TTM)
-19.03%
Return on equity (TTM)
-26.14%
Valuation
Price to book
2.08
Price to tangible book (TTM)
2.08
Price to free cash flow (TTM)
-6.953
Free cash flow yield (TTM)
-14.38%
Free cash flow per share (TTM)
-3.264
Growth
Earnings per share change (TTM)
-29.23%
What the Analysts think about Tourmaline Bio
Analyst ratings (Buy, Hold, Sell) for Tourmaline Bio stock.
Bulls say / Bears say
Tourmaline Bio's strong cash position of $275.3 million as of March 31, 2025, provides a runway into the second half of 2027, supporting ongoing and future clinical trials. (biospace.com)
The initiation of the Phase 2 TRANQUILITY trial in April 2024 for pacibekitug in cardiovascular inflammation indicates progress in their pipeline, with topline data expected in the first half of 2025. (globenewswire.com)
Tourmaline Bio completed an underwritten follow-on public offering in January 2024, raising gross proceeds of $172.5 million, enhancing their financial flexibility for development activities. (globenewswire.com)
Tourmaline Bio reported a net loss of $22.2 million for Q4 2024, up from $12.9 million in Q4 2023, reflecting increased operating expenses. (ir.tourmalinebio.com)
The company's research and development expenses rose to $20.5 million in Q4 2024 from $8.0 million in Q4 2023, indicating higher cash burn without corresponding revenue. (ir.tourmalinebio.com)
As a pre-revenue clinical-stage biotech, Tourmaline Bio's financial sustainability is contingent on successful clinical outcomes and future funding. (stockinvest.us)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
Tourmaline Bio Financial Performance
Revenues and expenses
Tourmaline Bio Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tourmaline Bio stock?
Tourmaline Bio (TRML) has a market cap of $583M as of July 30, 2025.
What is the P/E ratio for Tourmaline Bio stock?
The price to earnings (P/E) ratio for Tourmaline Bio (TRML) stock is 0 as of July 30, 2025.
Does Tourmaline Bio stock pay dividends?
No, Tourmaline Bio (TRML) stock does not pay dividends to its shareholders as of July 30, 2025.
When is the next Tourmaline Bio dividend payment date?
Tourmaline Bio (TRML) stock does not pay dividends to its shareholders.
What is the beta indicator for Tourmaline Bio?
Tourmaline Bio (TRML) does not currently have a Beta indicator.